verapamil has been researched along with Diabetes Mellitus, Type 1 in 18 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Current study aimed to appraise the potential therapeutic benefits of pharmacological inhibition of TXNIP using verapamil in diabetic retinopathy." | 8.02 | Inhibition of thioredoxin-interacting protein and inflammasome assembly using verapamil mitigates diabetic retinopathy and pancreatic injury. ( Eissa, LD; El-Azab, MF; Ghobashy, WA, 2021) |
| "SEVERAL MECHANISMS: The progression in renal failure first implies hemodynamic mechanisms and among which angiotensin II has a central role, but also an increase in proteinuria and the induction of many inflammatory and mitogenic mediators that enhance fibrosis (TGF-beta), an effect stimulating the thrombotic mechanism." | 4.81 | [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. ( Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L, 2002) |
| " Current study aimed to appraise the potential therapeutic benefits of pharmacological inhibition of TXNIP using verapamil in diabetic retinopathy." | 4.02 | Inhibition of thioredoxin-interacting protein and inflammasome assembly using verapamil mitigates diabetic retinopathy and pancreatic injury. ( Eissa, LD; El-Azab, MF; Ghobashy, WA, 2021) |
| "The 2 patients with recurrences are now successfully treated with a calcium channel blocker, an approach, to our knowledge, never before reported for adult-onset nesidioblastosis." | 2.41 | Adult-onset nesidioblastosis causing hypoglycemia: an important clinical entity and continuing treatment dilemma. ( Costa, EA; Kaplan, EL; Koka, MR; Straus II, FH; Sugg, SL; Witteles, RM, 2001) |
| "Verapamil promotes functional β-cell mass and improves glucose homeostasis in diabetic mice and humans with type 1 diabetes (T1D)." | 1.91 | Verapamil Prevents Decline of IGF-I in Subjects With Type 1 Diabetes and Promotes β-Cell IGF-I Signaling. ( Chen, J; Lu, B; Qian, WJ; Sethupathy, P; Shalev, A; Xu, G, 2023) |
| "Serum from patients with IDDM increased L-type calcium channel activity of insulin-producing cells and of GH3 cells derived from a pituitary tumor." | 1.29 | Increased activity of L-type Ca2+ channels exposed to serum from patients with type I diabetes. ( Ammälä, C; Bokvist, K; Dypbukt, J; Hallberg, A; Juntti-Berggren, L; Larsson, O; Nicotera, P; Orrenius, S; Rorsman, P; Wåhlander, K, 1993) |
| " Forearm blood flow was determined by venous occlusion plethysmography, and dose-response curves were generated for each drug." | 1.29 | Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. ( Creager, MA; Creager, SJ; Cusco, JA; Johnstone, MT; Lee, BK; Scales, KM, 1993) |
| "Verapamil was more effective than nifedipine in improving natriuresis and ANP release to saline load and in lowering the albumin excretion rate." | 1.28 | Effects of angiotensin converting enzyme inhibitors and calcium antagonists on atrial natriuretic peptide release and action and on albumin excretion rate in hypertensive insulin-dependent diabetic patients. ( Abaterusso, C; Brocco, E; Carraro, A; Cipollina, MR; Fioretto, P; Frigato, F; Muollo, B; Riva, F; Trevisan, M; Velussi, M, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.11) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 7 (38.89) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, G | 3 |
| Grimes, TD | 1 |
| Grayson, TB | 2 |
| Chen, J | 2 |
| Thielen, LA | 2 |
| Tse, HM | 1 |
| Li, P | 2 |
| Kanke, M | 1 |
| Lin, TT | 1 |
| Schepmoes, AA | 1 |
| Swensen, AC | 1 |
| Petyuk, VA | 1 |
| Ovalle, F | 2 |
| Sethupathy, P | 2 |
| Qian, WJ | 2 |
| Shalev, A | 3 |
| Pham, VT | 1 |
| Ciccaglione, M | 1 |
| Ramirez, DG | 1 |
| Benninger, RKP | 1 |
| Forlenza, GP | 2 |
| McVean, J | 1 |
| Beck, RW | 1 |
| Bauza, C | 1 |
| Bailey, R | 1 |
| Buckingham, B | 1 |
| DiMeglio, LA | 1 |
| Sherr, JL | 1 |
| Clements, M | 1 |
| Neyman, A | 1 |
| Evans-Molina, C | 1 |
| Sims, EK | 1 |
| Messer, LH | 1 |
| Ekhlaspour, L | 1 |
| McDonough, R | 1 |
| Van Name, M | 1 |
| Rojas, D | 1 |
| Beasley, S | 1 |
| DuBose, S | 1 |
| Kollman, C | 1 |
| Moran, A | 1 |
| Schamberger, MS | 1 |
| Buckingham, BA | 1 |
| Hsu, NC | 1 |
| Tsai, HB | 1 |
| Hsu, CH | 1 |
| Lu, B | 1 |
| Eissa, LD | 1 |
| Ghobashy, WA | 1 |
| El-Azab, MF | 1 |
| Grimes, T | 1 |
| Patel, AJ | 1 |
| Lam, TKT | 1 |
| Cherney, DZI | 1 |
| Bernadet-Monrozies, P | 1 |
| Rostaing, L | 1 |
| Kamar, N | 1 |
| Durand, D | 1 |
| Juntti-Berggren, L | 1 |
| Larsson, O | 1 |
| Rorsman, P | 1 |
| Ammälä, C | 1 |
| Bokvist, K | 1 |
| Wåhlander, K | 1 |
| Nicotera, P | 1 |
| Dypbukt, J | 1 |
| Orrenius, S | 1 |
| Hallberg, A | 1 |
| Elliott, WJ | 1 |
| Johnstone, MT | 1 |
| Creager, SJ | 1 |
| Scales, KM | 1 |
| Cusco, JA | 1 |
| Lee, BK | 1 |
| Creager, MA | 1 |
| Witteles, RM | 1 |
| Straus II, FH | 1 |
| Sugg, SL | 1 |
| Koka, MR | 1 |
| Costa, EA | 1 |
| Kaplan, EL | 1 |
| Fioretto, P | 1 |
| Frigato, F | 1 |
| Velussi, M | 1 |
| Riva, F | 1 |
| Muollo, B | 1 |
| Carraro, A | 1 |
| Brocco, E | 1 |
| Cipollina, MR | 1 |
| Abaterusso, C | 1 |
| Trevisan, M | 1 |
| Calver, A | 1 |
| Collier, J | 1 |
| Vallance, P | 1 |
| Shub, C | 1 |
| Vlietstra, RE | 1 |
| McGoon, MD | 1 |
| Bruserud, O | 1 |
| Thorsby, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)[NCT04545151] | Phase 2 | 138 participants (Anticipated) | Interventional | 2021-02-08 | Recruiting | ||
| The Effects of Watermelon Juice Supplementation on Postprandial Vascular Endothelial Function and Blood Flow During Hyperglycemia: A Pilot Study[NCT04092439] | 18 participants (Actual) | Interventional | 2019-09-12 | Completed | |||
| The Effect of Type 1 Diabetes on Pan-Arterial Vascular Function and Insulin Sensitivity in Humans[NCT02490124] | 7 participants (Actual) | Observational | 2014-12-31 | Completed | |||
| The Impact of Fitness and Mineralocorticoid Receptor Blockade on Vascular Dysfunction in Adults With Type 1 Diabetes[NCT03174288] | 32 participants (Actual) | Interventional | 2015-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for verapamil and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2002 |
Adult-onset nesidioblastosis causing hypoglycemia: an important clinical entity and continuing treatment dilemma.
Topics: Adult; Age of Onset; Calcium Channel Blockers; Combined Modality Therapy; Diabetes Mellitus, Type 1; | 2001 |
Selection of optimal drug therapy for the patient with angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Blood Pressure; Calcium Channel | 1985 |
1 trial available for verapamil and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Verapamil and beta cell function in adults with recent-onset type 1 diabetes.
Topics: Adult; Blood Pressure; Diabetes Mellitus, Type 1; Heart Rate; Humans; Insulin; Insulin-Secreting Cel | 2018 |
14 other studies available for verapamil and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes.
Topics: Diabetes Mellitus, Type 1; Humans; Immunologic Factors; Immunotherapy; Insulin; Verapamil | 2022 |
Ultrasound Imaging of Pancreatic Perfusion Dynamics Predicts Therapeutic Prevention of Diabetes in Preclinical Models of Type 1 Diabetes.
Topics: Animals; Diabetes Mellitus, Type 1; Islets of Langerhans; Mice; Mice, Inbred NOD; Mice, SCID; Pancre | 2022 |
Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial.
Topics: Adolescent; C-Peptide; Child; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Humans; Hypogl | 2023 |
Verapamil and Pancreatic Beta Cell Function in Pediatric Type 1 Diabetes-Reply.
Topics: Calcium Channel Blockers; Child; Diabetes Mellitus, Type 1; Humans; Insulin-Secreting Cells; Verapam | 2023 |
Verapamil and Pancreatic Beta Cell Function in Pediatric Type 1 Diabetes.
Topics: Calcium Channel Blockers; Child; Diabetes Mellitus, Type 1; Humans; Insulin-Secreting Cells; Verapam | 2023 |
Verapamil Prevents Decline of IGF-I in Subjects With Type 1 Diabetes and Promotes β-Cell IGF-I Signaling.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glucose; Humans; Insulin-Like G | 2023 |
Inhibition of thioredoxin-interacting protein and inflammasome assembly using verapamil mitigates diabetic retinopathy and pancreatic injury.
Topics: Angiogenesis Inhibitors; Animals; Blood Glucose; Calcium Channel Blockers; Cell Cycle Proteins; Diab | 2021 |
Beta cell preservation in patients with type 1 diabetes.
Topics: Adult; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Insulin-Secreting Cells; Verapa | 2018 |
Increased activity of L-type Ca2+ channels exposed to serum from patients with type I diabetes.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1993 |
An individualized approach to the hypertensive patient with renal disease: six illustrative case studies.
Topics: Adrenergic alpha-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Arterial Occlusive Dis | 1995 |
Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.
Topics: Adult; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothe | 1993 |
Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.
Topics: Adult; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothe | 1993 |
Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.
Topics: Adult; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothe | 1993 |
Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.
Topics: Adult; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothe | 1993 |
Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.
Topics: Adult; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothe | 1993 |
Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.
Topics: Adult; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothe | 1993 |
Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.
Topics: Adult; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothe | 1993 |
Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.
Topics: Adult; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothe | 1993 |
Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.
Topics: Adult; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothe | 1993 |
Effects of angiotensin converting enzyme inhibitors and calcium antagonists on atrial natriuretic peptide release and action and on albumin excretion rate in hypertensive insulin-dependent diabetic patients.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Calcium Cha | 1992 |
Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes.
Topics: Acetylcholine; Adult; Arginine; Arm; Diabetes Mellitus, Type 1; Humans; Male; Nitric Oxide; Nitropru | 1992 |
T lymphocyte responses to Coxsackie B4 and mumps virus. I. Influence of HLA-DR restriction elements.
Topics: Aminophylline; Antigens, Viral; Diabetes Mellitus, Type 1; Enterovirus; Herpesvirus 3, Human; Histoc | 1985 |